The main risk is not that the product is imaginary; it is that Stem may prove to be useful but not financially powerful. If software growth, retention, and implementation quality hold, the stock can
rerate from a distressed base. If project formation stays policy-gated, pricing stays soft, or financing flexibility tightens, the operating layer may remain strategically relevant while the equity underperforms anyway.